Literature DB >> 27678022

Clinical and Molecular Characterization of Community-Onset Urinary Tract Infections Due to Extended-Spectrum Cephalosporin-Resistant Enterobacteriaceae.

Judith A Anesi1, Ebbing Lautenbach1, Irving Nachamkin2, Charles Garrigan2, Warren B Bilker3, Mary Wheeler3, Pam Tolomeo3, Jennifer H Han1.   

Abstract

OBJECTIVE To evaluate risk factors for and molecular characteristics of community-onset extended-spectrum cephalosporin-resistant (ESC-R) Enterobacteriaceae (EB) urinary tract infections (UTIs) in a US health system. DESIGN Case-control study. PARTICIPANTS All patients presenting to the emergency department or outpatient practices with EB UTIs from December 21, 2010, through April 22, 2013, were included. Case patients had ESC-R EB UTIs. Control patients had ESC-susceptible EB UTIs and were matched 1:1 on study year. METHODS Risk factors for ESC-R EB UTI were assessed using multivariable conditional logistic regression. A subset of case isolates was evaluated for extended-spectrum beta-lactamases. RESULTS A total of 302 patients with community-onset EB UTI were included, of which 151 were cases. On multivariable analysis, risk factors for ESC-R EB UTI included trimethoprim-sulfamethoxazole use in the prior 6 months (odds ratio, 2.40 [95% CI, 1.22-4.70]; P=.01), older age (1.03 [1.01-1.04]; P<.001), diabetes (2.91 [1.32-6.41]; P=.008), and presentation to the emergency department ( 2.42 [1.31-4.46]; P=.005). The prevalence of extended-spectrum beta-lactamases among 120 case isolates was 52% CTX-M, 29% TEM, 20% OXA, and 13% SHV. The prevalence of AmpC was 25%. Pulsed-field gel electrophoresis of the CTX-M Escherichia coli isolates showed no distinct clusters. CONCLUSIONS Use of trimethoprim-sulfamethoxazole, older age, diabetes, and presentation to the emergency department were associated with community-onset ESC-R EB UTI. There was a high prevalence of CTX-M among our community isolates. Further studies are needed to determine strategies to limit emergence of these organisms in the community. Infect Control Hosp Epidemiol 2016;1433-1439.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27678022      PMCID: PMC5440186          DOI: 10.1017/ice.2016.225

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  37 in total

1.  Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients.

Authors:  R Colodner; W Rock; B Chazan; N Keller; N Guy; W Sakran; R Raz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-02-19       Impact factor: 3.267

2.  Specificity of ertapenem susceptibility screening for detection of Klebsiella pneumoniae carbapenemases.

Authors:  Shannon E McGettigan; Kathleen Andreacchio; Paul H Edelstein
Journal:  J Clin Microbiol       Date:  2009-01-14       Impact factor: 5.948

3.  Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Authors:  Jesús Rodríguez-Baño; Juan C Alcalá; Jose M Cisneros; Fabio Grill; Antonio Oliver; Juan P Horcajada; Teresa Tórtola; Beatriz Mirelis; Gemma Navarro; María Cuenca; María Esteve; Carmen Peña; Ana C Llanos; Rafael Cantón; Alvaro Pascual
Journal:  Arch Intern Med       Date:  2008-09-22

4.  Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus.

Authors:  L M A J Muller; K J Gorter; E Hak; W L Goudzwaard; F G Schellevis; A I M Hoepelman; G E H M Rutten
Journal:  Clin Infect Dis       Date:  2005-06-16       Impact factor: 9.079

5.  Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial.

Authors:  D A Talan; W E Stamm; T M Hooton; G J Moran; T Burke; A Iravani; J Reuning-Scherer; D A Church
Journal:  JAMA       Date:  2000 Mar 22-29       Impact factor: 56.272

6.  Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum beta-lactamases in York, UK.

Authors:  C J Munday; G M Whitehead; N J Todd; M Campbell; P M Hawkey
Journal:  J Antimicrob Chemother       Date:  2004-08-04       Impact factor: 5.790

7.  Extended-spectrum beta-lactamase (ESBL)-producing enterobacteria: factors associated with infection in the community setting, Auckland, New Zealand.

Authors:  C T Moor; S A Roberts; G Simmons; S Briggs; A J Morris; J Smith; H Heffernan
Journal:  J Hosp Infect       Date:  2008-03-19       Impact factor: 3.926

8.  Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK.

Authors:  N Woodford; M E Ward; M E Kaufmann; J Turton; E J Fagan; D James; A P Johnson; R Pike; M Warner; T Cheasty; A Pearson; S Harry; J B Leach; A Loughrey; J A Lowes; R E Warren; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2004-09-03       Impact factor: 5.790

9.  Escherichia coli producing SHV-type extended-spectrum beta-lactamase is a significant cause of community-acquired infection.

Authors:  Jesús Rodríguez-Baño; Juan Alcalá; Jose Miguel Cisneros; Fabio Grill; Antonio Oliver; Juan Pablo Horcajada; Teresa Tórtola; Beatriz Mirelis; Gemma Navarro; María Cuenca; María Esteve; Carmen Peña; Ana C Llanos; Rafael Cantón; Alvaro Pascual
Journal:  J Antimicrob Chemother       Date:  2009-02-17       Impact factor: 5.790

10.  Temporal trends of extended-spectrum cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae isolates in in- and outpatients in Switzerland, 2004 to 2011.

Authors:  A Kronenberg; M Hilty; A Endimiani; K Muhlemann
Journal:  Euro Surveill       Date:  2013-05-23
View more
  7 in total

1.  Colonization With Levofloxacin-resistant Extended-spectrum β-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients.

Authors:  Michael J Satlin; Kalyan D Chavda; Thomas M Baker; Liang Chen; Elena Shashkina; Rosemary Soave; Catherine B Small; Samantha E Jacobs; Tsiporah B Shore; Koen van Besien; Lars F Westblade; Audrey N Schuetz; Vance G Fowler; Stephen G Jenkins; Thomas J Walsh; Barry N Kreiswirth
Journal:  Clin Infect Dis       Date:  2018-11-13       Impact factor: 9.079

Review 2.  Systematic Review of Literature Examining Bacterial Urinary Tract Infections in Diabetes.

Authors:  Santosh Paudel; Preeti P John; Seyedeh Leila Poorbaghi; Tara M Randis; Ritwij Kulkarni
Journal:  J Diabetes Res       Date:  2022-05-17       Impact factor: 4.061

3.  Risk Factors for Extended-Spectrum β-lactamase-Producing Enterobacterales Bloodstream Infection Among Solid-Organ Transplant Recipients.

Authors:  Judith A Anesi; Ebbing Lautenbach; Pranita D Tamma; Kerri A Thom; Emily A Blumberg; Kevin Alby; Warren B Bilker; Alissa Werzen; Pam Tolomeo; Jacqueline Omorogbe; Lisa Pineles; Jennifer H Han
Journal:  Clin Infect Dis       Date:  2021-03-15       Impact factor: 9.079

4.  A Clinical Prediction Tool for Extended-Spectrum Cephalosporin Resistance in Community-Onset Enterobacterales Urinary Tract Infection.

Authors:  Erica J Weinstein; Jennifer H Han; Ebbing Lautenbach; Irving Nachamkin; Charles Garrigan; Warren B Bilker; Lois Dankwa; Mary Wheeler; Pam Tolomeo; Judith A Anesi
Journal:  Open Forum Infect Dis       Date:  2019-03-14       Impact factor: 3.835

5.  From Pathophysiological Hypotheses to Case-Control Study Design: Resistance from Antibiotic Exposure in Community-Onset Infections.

Authors:  Salam Abbara; Didier Guillemot; Christian Brun-Buisson; Laurence Watier
Journal:  Antibiotics (Basel)       Date:  2022-02-04

6.  Compared with Cotrimoxazole Nitroxoline Seems to Be a Better Option for the Treatment and Prophylaxis of Urinary Tract Infections Caused by Multidrug-Resistant Uropathogens: An In Vitro Study.

Authors:  Ulrich Dobrindt; Haleluya T Wami; Torsten Schmidt-Wieland; Daniela Bertsch; Klaus Oberdorfer; Herbert Hof
Journal:  Antibiotics (Basel)       Date:  2021-05-28

7.  Type 2 diabetes mellitus and antibiotic-resistant infections: a systematic review and meta-analysis.

Authors:  Rodrigo M Carrillo-Larco; Cecilia Anza-Ramírez; Giancarlo Saal-Zapata; David Villarreal-Zegarra; Jessica Hanae Zafra-Tanaka; Cesar Ugarte-Gil; Antonio Bernabé-Ortiz
Journal:  J Epidemiol Community Health       Date:  2021-07-29       Impact factor: 3.710

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.